PD-1-binding molecules and methods of use thereof

US10577422B2 · kind B2 · utility

Assignee

• Macrogenics, Inc. · US

Inventors

• Kalpana Shah · Rockville, US
• Douglas H. Smith · Boothwyn, US
• Ross La Motte-Mohs · Boyds, US
• Leslie S. Johnson · Travilah, US
• Paul A. Moore · North Potomac, US
• Ezio Bonvini · Potomac, US
• Scott Koenig · Rockville, US

Key dates

• Filing date: Jul 28, 2016
• Grant date: Mar 3, 2020
• Expiry date: Jul 28, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to selected anti-PD-1 antibodies capable of binding to both cynomolgus monkey PD-1 and to human PD-1: PD-1 mAb 1, PD-1 mAb 2, PD-1 mAb 3, PD-1 mAb 4, PD-1 mAb 5, PD-1 mAb 6, PD-1 mAb 7, PD-1 mAb 8, PD-1 mAb 9, PD-1 mAb 10, PD-1 mAb 11, PD-1 mAb 12, PD-1 mAb 13, PD-1 mAb 14, or PD-1 mAb 15, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to PD-1-binding molecules that comprise PD-1 binding fragments of such anti-PD-1 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such PD-1-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of using molecules that bind PD-1 for stimulating immune responses, as well as methods of detecting PD-1.